Diabetes drug development according to Tufts

Melissa Fassbender’s recent article on Outsourcing Pharma tells us that diabetes drug development is riskier than most other drug development according to Tufts Center for the Study of Drug Development.  Fassbender’s article has the data from Tufts’ study to share.  The take away is that diabetes therapies take longer to develop than other drug therapies and undergo stringent FDA regulations to assure cardiovascular risks are fully investigated.  Much needed drug therapies, riskier to develop than other drugs, it’s like “pushing an elephant up the stairs”, doing something very hard, but don’t stop now pharma groups, patients are waiting. Pearl has in-depth diabetes and metabolic disorders expertise.  Need help with your clinical program in diabetes?  Contact us for help with your clinical study, IRB reviews, or regulatory compliance issues.